Nanoscope Therapeutics Revenue
Biotechnology Research • 
Dallas, Texas, United States • 21-50 Employees
Nanoscope Therapeutics revenue & valuation
| Annual revenue | $4,192,195 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $13,500,000 |
| Total funding | $1,500,000 |
Key Contacts at Nanoscope Therapeutics
Ananta Laxmi Ayyagari
Director Regulatory Affairs And Intellectual Property
Subrata Batabyal
Director, Nonclinical Development
Navaneeth Kumar
Associate Director Quality Assurance
Brett Kiedaisch
Associate Director, Analytical Development & Qc
Samuel Pacilli
Director Project Management
Anish Patel
Associate Director, Value And Access
Mark Von Tress
Sr. Director Of Statistics
Company overview
| Headquarters | 2777 N Stemmons Fwy, Dallas, Texas 75207, US |
| Phone number | +120212025 |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Founded | 2017 |
| Employees | 21-50 |
| Socials |
Nanoscope Therapeutics Email Formats
Nanoscope Therapeutics uses 4 email formats. The most common is {first initial}{last name} (e.g., jdoe@nanostherapeutics.com), used 60% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@nanostherapeutics.com | 60% |
{first name}{last name} | johndoe@nanostherapeutics.com | 26.7% |
{first initial}{second initial}{last name} | jodoe@nanostherapeutics.com | 6.7% |
{last name}{last name} | doedoe@nanostherapeutics.com | 6.7% |
About Nanoscope Therapeutics
Nanoscope Therapeutics is developing disease-agnostic, vision-restoring optogenetic therapy for millions of patients blinded by retinal degenerative diseases. Following positive results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for retinitis pigmentosa (RP) (NCT04945772), a rolling BLA submission to the FDA has been initiated. If approved, MCO-010 has the potential to be the standard of care for RP patients, administered as a one-time, in-office injection without the need for genetic testing. The company has also shown promising results in the STARLIGHT Phase 2 clinical trial of MCO-010 in Stargardt disease (SD) (NCT05417126) and plans to initiate a Phase 3 registrational trial in 2025. MCO-010 has received FDA Fast Track and Orphan Drug designations for both RP and SD and EMA Orphan Drug Designation to cover non-syndromic and syndromic rod- and cone-dominant dystrophies, as well as macular dystrophies. A Phase 2 program for MCO in geographic atrophy (GA) patients is expected to start by the end of 2025. Other IND-ready programs include Leber congenital amaurosis (LCA). 8.25
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Nanoscope Therapeutics has 24 employees across 7 departments.
Departments
Number of employees
Nanoscope Therapeutics Tech Stack
Discover the technologies and tools that power Nanoscope Therapeutics's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
Video players
Form builders
JavaScript libraries
JavaScript libraries
UI frameworks
JavaScript libraries
CDN
Font scripts
JavaScript libraries
Miscellaneous
Security
Saudi Arabia
Bahrain
Australia
Frequently asked questions
4.8
40,000 users
